Fluidigm Corp (FLDM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Fluidigm Corp (FLDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014317
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, callisto system, EP1 system, polaris system, juno system, and helios. It also provides custom assays such as SNP type assays, maxplar antibodies, delta gene assays and access array assays. Fluidigm offers software, which include fluidigm cytobank analysis, singular analysis toolset, SNP genotyping analysis, real-time PCR analysis, and digital PCR analysis. The company’s C1 system supports mRNA sequencing, DNA sequencing, miRNA analysis and additional applications through the C1 open app IFC. It has operations in France, Canada, Singapore, China, Japan, Australia, the UK and Germany. Fluidigm is headquartered in South San Francisco, California, the US.

Fluidigm Corp (FLDM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Fluidigm Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 12
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 14
Genome Institue of Singapore Partners With Fluidigm To Establish Single-Cell Genomics Research Center 15
DVS Sciences And Cytobank Enter Into Co-Development Agreement 16
Equity Offering 17
Fluidigm Raises USD30 Million in Public Offering of Shares 17
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 18
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 20
Debt Offering 22
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 22
Fluidigm Corp – Key Competitors 24
Fluidigm Corp – Key Employees 25
Fluidigm Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Aug 04, 2016: Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System 27
Jun 09, 2016: Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry 28
Financial Announcements 29
Nov 02, 2017: Fluidigm Announces Third Quarter Financial Results and Operational Progress 29
May 04, 2017: Fluidigm Announces First Quarter Financial Results 31
Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results 34
Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year 36
Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results 37
Oct 12, 2016: Fluidigm Announces Preliminary Third Quarter 2016 Revenue 39
Aug 04, 2016: Fluidigm Announces Q2 2016 Financial Results 40
May 05, 2016: Fluidigm Announces First Quarter Financial Results 42
Feb 04, 2016: Fluidigm Announces Q4-Full Year 2015 Financial Results 44
Jan 12, 2016: Fluidigm Announces Preliminary Full Year and Fourth Quarter 2015 Revenue 45
Corporate Communications 46
Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors 46
Oct 19, 2016: Fluidigm Names S. Christopher Linthwaite as New Chief Executive Officer 47
Aug 04, 2016: Fluidigm Appoints New President and Chief Operating Officer 48
Legal and Regulatory 49
Aug 04, 2016: Fluidigm Receives ISO 13485 And ISO 9001 Certification 49
Product News 50
Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Fluidigm Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10
Fluidigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 12
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 14
Genome Institue of Singapore Partners With Fluidigm To Establish Single-Cell Genomics Research Center 15
DVS Sciences And Cytobank Enter Into Co-Development Agreement 16
Fluidigm Raises USD30 Million in Public Offering of Shares 17
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 18
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 20
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 22
Fluidigm Corp, Key Competitors 24
Fluidigm Corp, Key Employees 25
Fluidigm Corp, Other Locations 26
Fluidigm Corp, Subsidiaries 26

★海外企業調査レポート[Fluidigm Corp (FLDM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LIG Nex1 Co., Ltd.:企業の戦略・SWOT・財務情報
    LIG Nex1 Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary LIG Nex1 Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • NovImmune SA-製薬・医療分野:企業M&A・提携分析
    Summary NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and ka …
  • Suheung Capsule Co Ltd (008490):企業の財務・戦略的SWOT分析
    Suheung Capsule Co Ltd (008490) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Europlasma SA (ALEUP):電力:M&Aディール及び事業提携情報
    Summary Europlasma SA (Europlasma) is a leading provider of clean technology and renewable energy solutions in Europe. The company along with its group companies offers plasma solutions to treat gas and hazardous waste and conducts waste disposal and power production from waste and biomass and recyc …
  • Allegra Orthopaedics Ltd (AMT):医療機器:M&Aディール及び事業提携情報
    Summary Allegra Orthopaedics Ltd (Allegra), develops, manufactures and sells prosthetic implants and related orthopedic medical devices. Its major products include adult and adolescent clavicle fixation system and pin; shoulder implants; proximal humeral plates; trauma distal radial plates and syste …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • China Datang Corp:電力:M&Aディール及び事業提携情報
    Summary China Datang Corp (CDT) is engaged in development, investment, construction, operation and management of power generation assets. The company provides electric power equipment, environment protection device, memory card and card reader; religion crafts, meter for electricity, safety products …
  • Quantum Utility Generation LLC:電力:M&Aディール及び事業提携情報
    Summary Quantum Utility Generation LLC (QUG) is an electric utility that acquires, develops, operates and optimizes power generation assets in the Americas. The utility generates electricity from various sources such as wind, coal and natural gas-based power generation plants. It also produces elect …
  • Nanotech Security Corp.:企業の戦略・SWOT・財務情報
    Nanotech Security Corp. - Strategy, SWOT and Corporate Finance Report Summary Nanotech Security Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Strukton Groep Nv
    Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report Summary Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PromptCare Inc-製薬・医療分野:企業M&A・提携分析
    Summary PromptCare Inc (PromptCare) is a healthcare center that respiratory products and home infusion services. The center provides respiratory services such as clinical support programs, patient-focused technology and testimonials. It provides home infusion therapies for patients of all ages with …
  • CH2M HILL Companies, Ltd.:企業の戦略・SWOT・財務情報
    CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Korea Electric Power Corporation (015760):企業の財務・戦略的SWOT分析
    Korea Electric Power Corporation (015760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Cold Spring Harbor Laboratory:製薬・医療:M&Aディール及び事業提携情報
    Summary Cold Spring Harbor Laboratory (CSHL) is a research and education institution that offers molecular biology and genetics services. The institution offers research services such as graduate research, research training, clinical research, quantitative biology research, postdoctoral research, di …
  • IHI Corp (7013):企業の財務・戦略的SWOT分析
    IHI Corp (7013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • American Eagle Outfitters Inc:企業の戦略・SWOT・財務情報
    American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report Summary American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Baltika Breweries LLC:戦略・SWOT・企業財務分析
    Baltika Breweries LLC - Strategy, SWOT and Corporate Finance Report Summary Baltika Breweries LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tata Motors Limited:企業の戦略・SWOT・財務分析
    Tata Motors Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Motors Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • NTN Corporation:企業の戦略・SWOT・財務情報
    NTN Corporation - Strategy, SWOT and Corporate Finance Report Summary NTN Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Avidity Biosciences LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Avidity Biosciences LLC (Avidity Biosciences), formerly Avidity NanoMedicines LLC is a biotech company that develops antibody oligonucleotide conjugates (AOCs). The company’s proprietary platform technology has enhanced pharmacokinetic and biodistribution properties that improves the deliver …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆